[Controversies and trends in ulcer therapy. 2: Prevention of recurrence].
Berndt
H
H
Universitätsklinik für Innere Medizin der Charité, Humboldt-Universität zu Berlin.
D000328:Adult; D000368:Aged; D001729:Bismuth / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000209:etiology / Q000517:prevention & control; D016480:Helicobacter pylori / Q000187:drug effects; D006635:Histamine H2 Antagonists / Q000008:administration & dosage; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage; D010437:Peptic Ulcer / Q000209:etiology / Q000517:prevention & control*; D012008:Recurrence; D013392:Sucralfate / Q000008:administration & dosage
D006635:Histamine H2 Antagonists; D013392:Sucralfate; D009853:Omeprazole; D001729:Bismuth
Kontroversen und Tendenzen in der Ulkustherapie. Teil 2: Rezidivprophylaxe.